Email updates

Keep up to date with the latest news and content from Stem Cell Research & Therapy and BioMed Central.

Commentary

Adipose-derived stem cells weigh in as novel therapeutics for acute lung injury

Kushagra Gupta1, Anja Hergrueter1 and Caroline A Owen12*

Author Affiliations

1 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 USA

2 Fellow of the Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA

For all author emails, please log on.

Stem Cell Research & Therapy 2013, 4:19  doi:10.1186/scrt167


See related research by Zhang et al., http://stemcellres.com/content/4/1/13

Published: 28 February 2013

Abstract

Acute lung injury is characterized by intense neutrophilic lung inflammation and increased alveolar-capillary barrier permeability leading to severe hypoxemia, and is associated with high mortality despite improvements in supportive care. There is an urgent need for effective therapies for acute lung injury. Zhang and colleagues tested the efficacy of adipose-derived stem cells in acute lung injury in mice. When adipose-derived stem cells were delivered to mice that had been challenged with lipopolysaccharide, they potently limited acute lung inflammation and injury in the mice, indicating that adipose-derived stem cells have therapeutic potential in acute lung injury in humans. Herein, we discuss the advantages and potential limitations of using adipose-derived stem cells as therapeutics for human acute lung injury.